Healthcare & Biotech

GRAIL's stock fell more than 20% after the NHS-Galleri trial—the world's largest real-world test of AI-based multi-cancer blood screening—missed its primary endpoint on February 1, 2026. The three-year UK study found no statistically significant reduction in late-stage cancer detections, undermining GRAIL's case for insurance reimbursement in the US and abroad. FDA approval timelines are now uncertain, leaving GRAIL dependent on a slower, lower-margin cash-pay market.

California-based Biomerica faces bankruptcy as operating losses drain cash reserves, with management warning the company may not survive 12 months. The medical diagnostics firm joins dozens of undercapitalized biotech companies worldwide struggling to commercialize intellectual property amid tightening venture capital flows. Shareholders face dilution or total loss as emergency financing options narrow.